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Introduction
Juvenile idiopathic arthritis (JIA) is a disease most com-
monly presenting as peripheral arthritis, and increased
inflammatory response due to endogenous and exogenous
antigens plays a role in its pathogenesis. Tuberculin skin
test (TST) is used to determine whether a person is
infected with Mycobacterium tuberculosis. In studies,
delayed type hypersensitivity response was found to be
suppressed in vitro among JIA patients. TST in JIA
patients was studied for the first time by our group. In
that study, PPD response was found not to be affected by
the distribution of subgroups of the disease, activity of the
disease or treatment (methotrexate, prednisolone). None
of the enrolled children in that study were using biological
drugs.
Objectives
The aim of our study was to investigate the effect of
biological drugs on PPD reaction mediated by Th1
immune response in a group of JIA patients who were
not involved in our previous study.
Methods
The study group consisted of 234 patients with the diag-
nosis of JIA according to ILAR diagnostic criteria and who
were using biological drugs, and 45 healthy controls. PPD
of the patients which was routinely done during the follow
up was obtained from the patient files. BCG vaccination
status of the patients and controls was similar. PPD
values ≥ 5 mm were considered positive. Subjects with
a PPD ≥ 10 mm were evaluated with the suspicion of
tuberculosis infection and those with the final diagnosis of
tuberculosis infection were given anti-tuberculosis drug
therapy.
Results
Of the 234 JIA patients on biological drug therapy,
102 (43.6%) were male and 132 (56.4%) were female. Age
distribution was 3.25-19,8 years, mean age was 12.8 ±
4.7 years. Disease duration ranged between 3 months and
17 years and mean duration of disease was 5.9 ±
4.11 years. Mean diameter of PPD indurations’ was
4,996 ± 6,8494 mm (diameter: 0- 40 mm) in JIA patients
and 7.83 ± 3.47 mm (diameter 0–16 mm ) in controls
(p = 0,0056). PPD positivity was found in 96 (%41) and 38
(%84,4) of the subjects in JIA and control groups, respec-
tively (p<0,0001). PPD≥10 mm was detected in 59 (%25,2)
and 19 (%42,2) subjects of the JIA and control groups,
respectively (p=0,03). PPD was negative in 125 (%53,4)
and 3 (%6,6) of the subjects in JIA and control groups,
respectively (p< 0,0001). When PPD induration was
reported with respect to the biological drugs that were
used; PPD was 4.632±6.3490 mm in 185 (79,1%) of the
subjects using etanercept (p=0,01), 4.957±9.1873 mm in
23 (9,8%) of the subjects using adalimumab (p=0,06),
8.391 ± 7.7386 mm in 23 (9,8%) of the subjects using
infliximab (p=0,6) and 1.667 ± 2.8868 mm in 3 (1,3%) of
the subjects using anakinra. There was no difference in
PPD response between patients using etanercept and ada-
limumab. PPD induration was larger in subjects using
Infliximab.
Conclusion
In patients with JIA who had infantile BCG vaccination
and who were currently on biological drugs, PPD
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induration was significantly lower compared to the control
group. There was no difference in PPD response between
patients who were on biological drugs or who were not
using drugs according to our two major studies. Prospec-
tive studies evaluating measurements of PPD reaction in
patients on biological drug therapy would provide further
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